3 results about "Induction immunosuppression" patented technology

The invention provides an inhalable T cell activation nano platform suitable for lung cancer immunotherapy and a preparation method and application thereof. The nano-platform comprises a MoS2-statin nano-platform formed by loading IL-2 and anti-PD-1 protein on a MoS2 nano-sheet, and the platform realizes the treatment effect through the following modes: by accurately controlling the particle size of nano-particles, the nano-particles can be efficiently deposited in a lung tumor area, the local drug concentration is remarkably improved, the whole body exposure is reduced, and the side effect of intravenous administration is avoided; the proliferation and immune response of CD8 + T cells are enhanced through the synergistic effect of IL-2, the drug resistance of PD-1 is reduced, and the treatment effect of the immune checkpoint inhibitor is improved in combination with the immunomodulatory function of MoS2; copper death of immunosuppressive Treg cells is induced through the MoS2 nano platform, the immunosuppressive cells in a tumor microenvironment are removed, the immune drug resistance bottleneck in immunotherapy is broken through, and an innovative treatment means with high targeting, remarkable curative effect and small side effect is provided for lung cancer patients.

Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and / or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.

To provide cells that are competitive against cancer cells without starving or becoming exhausted even in glucose-depleted environments. To provide cells that are effective in metabolic (e.g., low glucose, high lactate, high fatty acid) and immunological tumor environments (e.g., chemokine profiles that induce immunosuppressive immune cells, expression of checkpoint molecules, and infiltration of suppressor cells that negatively regulate anti-tumor immune responses, such as inhibitory cytokines and Treg cells) in which normal T cells or conventional genetically modified cells are inhibited from infiltrating and, even if they infiltrate, are unable to exert long-term effector function due to starvation or exhaustion. [Solution] T cells with effector function, which have been modified to express Foxp3 (including mutant and partially deleted forms) and / or have enhanced Foxp3 expression.